Due to the wide expression of CD19 in normal B cells as well as B cell-derived leukemia and lymphomas, there has been rapid development of immunotherapy strategies targeting this antigen, including bispecific T cell engagers (BiTEs) and chimeric antigen receptor (CAR) T-cells. The gene discussed is CD19; the disease is lymphoma.